Clinical Trial Update: 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia [Phase 2]

View source ↗

Summary

Phase 2 trial of 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer with bone marrow involvement and cytopenia has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pluvicto (177Lu-PSMA-617) (lutetium-177 PSMA-617)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Castration Resistant Prostate Cancer, Cytopenia | Phase 2 | Status: SUSPENDED